Initial characteristics of patients according to treatment group (CHVP vs HDT)
| Characteristics . | CHVP (n = 80) . | HDT (n = 86) . | P . |
|---|---|---|---|
| Median age, y (range) | 50 (29-61) | 51 (32-60) | .15 |
| Male/female, n | 47/33 | 38/48 | .017 |
| Histology, n | .03 | ||
| Grade I | 40 | 28 | |
| Grade II | 38 | 50 | |
| Grade III | 2 | 8 | |
| Ann Arbor stage, n | .1 | ||
| II | 6 | 4 | |
| III | 22 | 8 | |
| IV | 52 | 64 | |
| B symptoms present, n | 28 | 14 | .009 |
| Performance status grade, n | .1 | ||
| 0 | 44 | 39 | |
| 1 | 35 | 38 | |
| 2 or higher | 1 | 9 | |
| More than 4 nodal sites, n | 21 | 15 | .13 |
| Serum LDH higher than normal, n | 32 | 24 | .41 |
| FLIPI*, n | .4 | ||
| Low | 23 | 26 | |
| Intermediate | 31 | 40 | |
| High | 26 | 20 | |
| Mass > 10 cm, n | 28 | 25 | .77 |
| Characteristics . | CHVP (n = 80) . | HDT (n = 86) . | P . |
|---|---|---|---|
| Median age, y (range) | 50 (29-61) | 51 (32-60) | .15 |
| Male/female, n | 47/33 | 38/48 | .017 |
| Histology, n | .03 | ||
| Grade I | 40 | 28 | |
| Grade II | 38 | 50 | |
| Grade III | 2 | 8 | |
| Ann Arbor stage, n | .1 | ||
| II | 6 | 4 | |
| III | 22 | 8 | |
| IV | 52 | 64 | |
| B symptoms present, n | 28 | 14 | .009 |
| Performance status grade, n | .1 | ||
| 0 | 44 | 39 | |
| 1 | 35 | 38 | |
| 2 or higher | 1 | 9 | |
| More than 4 nodal sites, n | 21 | 15 | .13 |
| Serum LDH higher than normal, n | 32 | 24 | .41 |
| FLIPI*, n | .4 | ||
| Low | 23 | 26 | |
| Intermediate | 31 | 40 | |
| High | 26 | 20 | |
| Mass > 10 cm, n | 28 | 25 | .77 |
FLIPI was assessed retrospectively.